



BioCryst Ranked Number Five in Deloitte's 2010 Technology Fast 500(TM) Program for Fastest Growing Companies in North America

RESEARCH TRIANGLE PARK, N.C., Oct 20, 2010 (BUSINESS WIRE) -- BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that it has been named number five on Deloitte's 2010 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth over five years, from 2005-2009.

"We are pleased to be included for the third consecutive year in Deloitte's Technology Fast 500(TM) program in North America," said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst. "This achievement signifies the hard work and dedication of BioCryst employees as well as the Company's continued focus on building an enduring and successful biopharmaceutical company."

To qualify for the Deloitte Technology Fast 500(TM), companies must have had operating revenues of at least \$50,000 in 2005 and \$5 million in 2009, be headquartered in North America and be a company that owns proprietary technology or proprietary intellectual property that contributes to a majority of the company's operating revenues. Using other companies' technology or intellectual property in a unique way does not satisfy this requirement.

Overall, Technology Fast 500(TM) award winners for 2010 had revenue growth ranging from 146 percent to 164,079 percent from 2005 to 2009, with an average growth of 2,361 percent.

About Deloitte Technology Fast 500(TM)

The Deloitte Technology Fast 500(TM) provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Fast 500 Web site, and public company database research conducted by Deloitte. Technology Fast 500(TM) award winners for 2010 are determined based on percentage fiscal year revenue growth during the five year period from 2005 to 2009. The ranking includes both public and private companies. For more information please visit Deloitte's Web site at www.fast500.com.

As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

SOURCE: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals
Investors: Robert Bennett, 919-859-7910

Media: Catherine Collier Kyroulis, WCG, 212-301-7174

Copyright Business Wire 2010